• Reactive Oxygen Species Assay Kit: Advanced Insights for Pre

  2026-04-30

  Explore the science and new applications of the Reactive Oxygen Species Assay Kit using the DCFH-DA fluorescent probe. This article uniquely bridges molecular mechanisms with translational research needs, empowering oxidative stress measurement assay design.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-04-30

  This study reveals that reticulocalbin 2 (RCN2) promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) by enabling UBR5-mediated degradation of PPP2CA, leading to PI3K-AKT pathway activation. The findings provide mechanistic insight into ESCC progression and highlight RCN2 as a potential therapeutic target for overcoming treatment resistance.

• Polymyxin B Sulfate: Advanced Workflows in Infection Researc

  2026-04-29

  Polymyxin B (sulfate) from APExBIO empowers researchers to tackle multidrug-resistant Gram-negative bacteria and probe immune modulation with confidence. This guide offers workflow enhancements, troubleshooting strategies, and actionable protocol parameters—bridging reference-backed findings with practical laboratory execution.

• Resiniferatoxin (RTX): Precision TRPV1 Silencing in Analgesi

  2026-04-29

  Resiniferatoxin (RTX) delivers ultra-potent, targeted inactivation of TRPV1-positive sensory neurons, enabling long-lasting and reproducible analgesia in preclinical and emerging clinical applications. This guide translates the latest mechanistic insights and protocol advances into actionable workflows, troubleshooting approaches, and unique benefits for pain research.

• Bazedoxifene Targets IL-6/GP130 Signaling for Cancer Therapy

  2026-04-28

  Shi et al. (2024) review the repositioning of bazedoxifene (BZA), an FDA-approved SERM, as an inhibitor of the IL-6/GP130 pathway implicated in cancer progression. The study highlights BZA’s novel mechanism of disrupting pro-tumorigenic signaling, offering new avenues for targeted therapy and combinatorial strategies in oncology.

• Tolazoline in Translational Research: Mechanism, Models, and

  2026-04-28

  This thought-leadership article delivers a mechanistic and strategic perspective on Tolazoline, an α2-adrenergic receptor antagonist, for translational researchers. It integrates the latest evidence on neuroendocrine and airway smooth muscle modulation, guides protocol design, appraises competitive alternatives, and positions APExBIO’s Tolazoline as a critical tool for pioneering islet and airway studies. Expanding beyond routine product summaries, this piece bridges current literature with future translational opportunities, including the relevance of insulin signaling pathways in neurodegenerative disease models.

• Reelin-SFK Pathway: A Crucial Permissive Factor for Ketamine

  2026-04-27

  This study demonstrates that intact synaptic Reelin signaling via Apoer2 and Src family kinases is indispensable for ketamine-induced synaptic and behavioral antidepressant effects in mice. The findings clarify a molecular mechanism underlying nonresponsiveness to ketamine and provide a framework for further research into synaptic signaling in neuropsychiatric disorders.

• Super-Enhancer Hijacking of LINC01977 Drives Early LUAD by T

  2026-04-27

  Zhang et al. uncover that super-enhancer (SE) hijacking of the lncRNA LINC01977 promotes malignancy in early-stage lung adenocarcinoma (LUAD) through a canonical TGF-β/Smad3-dependent pathway. This study defines a novel feedback loop involving tumor-associated macrophages and identifies LINC01977 as a potential therapeutic target for early intervention in LUAD progression.

• Bufalin as a Cardiotoic Steroid: Optimizing Apoptosis in TNB

  2026-04-26

  Bufalin, a cardiotonic steroid from APExBIO, is redefining apoptosis induction and molecular target degradation in triple-negative breast cancer (TNBC) and hepatocellular carcinoma research. This deep dive connects the latest mechanistic evidence with practical workflows, protocol parameters, and hands-on troubleshooting tips to maximize reproducibility and insight in oncology labs.

• Dopamine Transporter Imaging Tracks Neuron Maturation in PD

  2026-04-25

  Goggi et al. (2020) demonstrate that dopamine transporter (DAT) neuroimaging via PET accurately assesses the in vivo maturation of human embryonic stem cell-derived midbrain dopaminergic neurons in a rat model of Parkinson’s disease. This approach provides a non-invasive, quantitative method for evaluating cell therapy efficacy, advancing both preclinical research and translational potential.

• Tropifexor (LJN452): Advancing FXR Modulation in Epithelial

  2026-04-24

  Tropifexor (LJN452) stands out as a gold-standard FXR agonist for dissecting intestinal epithelial barrier function, offering nanomolar potency and translational relevance. Its use in both in vivo and organoid models enables reproducible, mechanistically driven metabolic and liver disease research.

• Ethacridine Lactate Monohydrate: Precision Antiseptic in Cel

  2026-04-24

  Ethacridine lactate monohydrate offers high-purity, robust microbial control for sensitive biochemical and cell-based assays. This guide details optimized protocols, experimental troubleshooting, and advanced applications in stem cell and chromatin studies, helping researchers maximize data fidelity and reproducibility with APExBIO's trusted research-grade compound.

• IWR-1-endo: Wnt Signaling Inhibitor for Reproducible Assays

  2026-04-23

  IWR-1-endo stands out as a potent Wnt signaling inhibitor, enabling precise modulation of β-catenin activity in cancer and regenerative models. This guide unpacks optimized workflows, troubleshooting strategies, and actionable insights for maximizing assay reliability in advanced Wnt/β-catenin pathway research.

• Acetylcysteine in 3D Tumor Models: Applied Workflows & Tips

  2026-04-23

  Acetylcysteine (N-acetyl-L-cysteine) from APExBIO enables precise modulation of oxidative stress and redox balance in advanced 3D tumor-stroma models. This article translates cutting-edge research—including patient-specific chemoresistance studies—into actionable protocols, troubleshooting strategies, and comparative insights for hepatic, respiratory, and oncology workflows.

• Quizartinib (AC220): Reliable FLT3 Inhibition for AML Resear

  2026-04-22

  This article provides a scenario-driven, evidence-based exploration of Quizartinib (AC220) (SKU A5793) for acute myeloid leukemia (AML) research workflows. It addresses practical challenges in kinase inhibition assays, data reproducibility, and product reliability. Bench scientists will find protocol guidance and comparative insights to optimize FLT3 signaling studies using Quizartinib (AC220).

15186 records 1/1013 page Next 12345 下5页 Last page